LC-MS/MS法检测水环境中的双氯芬酸钠

本研究报道了一种高灵敏度的测定水环境中双氯芬酸钠残留的LC-MS/MS法。色谱和质谱条件为:色谱柱为ACQUITY UPLC?BEH C_(18)柱(50 mm×2. 1 mm,1. 7μm),流动相为乙腈-水(60∶40,V/V),流速0. 30mL·min~(-1); AB SCIEX QTRAP 5500质谱仪,电喷雾离子源(ESI),雾化器压力30 psi,离子源温度550°C。双氯芬酸钠分子量为318. 13,在负离子扫描模式下,一级和二级质谱分别得到m/z为293. 8和249. 9的峰。此法做出的双氯芬酸钠标准曲线浓度范围为0. 20~20. 00 ng·mL~(-1)(r=0. 9994),定量下限为0. 05 ng·mL~(-1)。双氯芬酸钠的回收率在67. 2%~104%之间。该方法灵敏度高,操作简便快速,可用于水环境中双氯芬酸钠的检测。     

柱前衍生-HPLC-MS内标法测定动物组织中棉酚旋光异构体的含量

建立(R)-(-)-2-氨基-1-丙醇柱前衍生高效液相色谱-质谱法测定大鼠血浆、肝脏和肌肉组织中棉酚旋光异构体含量的检测方法。使用(R)-(-)-2-氨基-1-丙醇作为衍生试剂对棉酚进行柱前衍生,采用YMC-Pack ODS-AM(150×3.0 mm,3μm)色谱柱,以乙腈-1.0%甲酸(85∶15)为流动相进行洗脱。在电喷雾正离子模式下对甘草次酸、(-)-棉酚和(+)-棉酚进行选择性离子检测,检测离子质荷比分别为[M+H]~+m/z 471.4和[M+H]~+m/z 633.4。棉酚在血浆中平均回收率为90.1~109.8%,在肝脏中平均回收率为95.1~105.4%,在肌肉中平均回收率为90.2~106.6%;(-)-棉酚和(+)-棉酚的检出限分别为2.84 ng·mL~(-1)和3.43 ng·mL~(-1)。该方法检测限低,灵敏度高,为制定动物源性食品中游离棉酚旋光异构体检测标准提供一定参考。     

超高效液相色谱-串联质谱法测定水中阿莫西林的残留量

采用超高效液相色谱-串联质谱法测定水中低含量的阿莫西林残留。将水样用亲水性聚四氟乙烯针式滤器进行过滤,以Kinetex 2.6μm C_(18)色谱柱为分离柱,以0.01%(体积分数)甲酸溶液-乙腈混合液为流动相进行梯度洗脱,质谱分析中选择电喷雾正离子源和多反应监测模式,用外标法进行定量。阿莫西林的峰面积与其质量浓度在0.020~1.50μg·L~(-1)范围内呈线性关系,检出限(3S/N)为10 ng·L~(-1),测定下限(10S/N)为20 ng·L~(-1)。加标回收率在91.3%~105%之间,测定值的相对标准差(n=6)小于6.0%。     

超高效液相色谱-串联质谱法测定减肥类保健品中的西布曲明

采用超高效液相色谱-串联质谱法测定减肥类保健品中的西布曲明。样品经甲醇超声提取后,使用Phenomenex Kinetex C18色谱柱分离,以乙腈-10mmol·L-1乙酸铵溶液(含0.1%甲酸)为流动相进行梯度洗脱,质谱中选择多反应选择离子监测模式检测,以西布曲明-D6作为同位素内标进行定量。西布曲明的质量浓度在5.00~400μg·L-1范围内呈线性,测定下限(10S/N)为10ng·g-1。加标回收率在97.0%~104%之间,相对标准偏差(n=9)为1.1%~3.0%。     

高效液相色谱-串联质谱法检测发酵液中的印楝素A

建立了一种高效液相色谱-电喷雾电离串联质谱联用仪(HPLC-MS/MS)检测发酵液中印楝素A的方法。样品经有机溶剂萃取,旋转蒸发浓缩,乙腈溶解定容,以Kinete C_(18)色谱柱(2.1 mm×100 mm,2.6μm)分离。流动相0.1%甲酸乙腈溶液和0.1%甲酸水溶液,体积比为45:55,总流速为0.2 mL·min~(-1)。电喷雾正离子电离(ESI~+)方式,多反应监测(MRM)模式下进行质谱检测,基质匹配外标法定量。目标物在6～48 ng·mL~(-1)之间线性关系良好,相关系数R=0.9993,检出限(3S/N)为0.5 ng·mL~(-1),日间重复性RSD=1.279%(n=3)。三个添加水平下(6、24、48 ng·mL~(-1))平均回收率为81.5%～87.4%,RSD为3.1%～4.4%。该方法样品前处理简单,分析时间短,准确度、精确度高,可用于发酵液中印楝素A的痕量检测。     

高效液相色谱-串联质谱法测定茶叶、三七中胺苯磺隆和甲基胺苯磺隆的残留量北大核心CSCD

建立了测定茶叶、三七中胺苯磺隆和甲基胺苯磺隆残留量的高效液相色谱-串联质谱法。样品经超纯水浸泡,乙腈提取,QuEChERS净化,Phenomenex Kinetex C 18色谱柱(50×2.1 mm,2.6μm)分离,液相色谱-串联质谱法检测,基质匹配外标法定量。胺苯磺隆和甲基胺苯磺隆在1.0 ng/mL~100 ng/mL范围内线性关系良好,相关系数R均大于0.999,方法的检出限(S/N=3)为0.07μg/kg~0.20μg/kg,定量限(S/N=10)为0.21μg/kg~0.60μg/kg。在5μg/kg~100μg/kg范围的回收实验中,胺苯磺隆平均回收率为70.8%~108.1%,相对标准偏差(RSD,n=6)为3.3%~11.4%;甲基胺苯磺隆平均回收率为70.2%~105.5%,RSD(n=6)为2.9%~10.6%。本方法前处理简单、稳定、灵敏,适用于茶叶、三七中胺苯磺隆和甲基胺苯磺隆残留量的同时测定。     

液相色谱-串联质谱法测定宠物食品中赭曲霉毒素A和B

建立了同时测定宠物食品中赭曲霉毒素A和B的液相色谱-串联质谱分析方法。样品经乙腈/水(1∶1,V/V)提取,HLB固相萃取柱净化。采用Agilent ZOBRAX C_(18)柱(150×2.1mm,5μm)分离,以0.1%甲酸水溶液-乙腈作为流动相,梯度洗脱。目标化合物在多反应监测模式(MRM)下进行检测,外标法定量。在优化的条件下,赭曲霉毒素A和B在0.1~10.0ng·mL~(-1)范围内呈良好的线性关系,相关系数均不低于0.9993,方法定量限分别为0.1μg·kg~(-1)和0.05μg·kg~(-1)。方法平均回收率为78.3%~107.5%,相对标准偏差不大于9.5%。该方法前处理简单、选择性好、灵敏度高,可用于宠物食品中赭曲霉毒素A和B的测定。     

高效液相色谱-串联质谱法测定人血浆中消旋卡多曲活性代谢物含量

建立高效液相色谱-串联质谱法(HPLC-MS/MS)测定人血浆中消旋卡多曲活性代谢物Thiorphan(TP)的含量及S-Methyl-Thiorphan(MTP)的相对含量。采用Kromasil C18色谱柱(25mm×4.6mm,5μm),流动相为V(水)∶V(乙腈)=72∶28,甲酸调pH至2.8。加抗氧化剂的血浆样品经乙腈直接沉淀后进样、MRM模式外标法定量,TP和MTP检测离子对分别为m/z252/218和m/z266/218。TP在6.25~3200μg/L范围内线性关系良好(r=0.9998);方法回收率为97.1%~109.0%,批内批间RSD分别小于3.5%及6.0%。     

液质联用检测人体血浆中的阿奇霉素

采用高效液相色谱串联质谱技术(HPLC-MS/MS)测定人体血浆中阿奇霉素的浓度. 选用Lichrospher CN 柱, 流动相为V(乙腈)∶V(水)=40∶60(水中含体积分数为0.1%的甲酸和质量分数为0.1%的醋酸铵), 电喷雾离子源正离子方式检测. 该方法在2.34~600 ng/mL范围内线性关系良好, 定量下限为2.34 ng/mL(S/N>10), 回收率94.13%~97.42%, 基质效应92.50%~107.87%, 日内和日间测定药物浓度的相对标准偏差(RSD)均小于10.0%. 用该方法测定了24名男性健康志愿者单剂量口服500 mg阿奇霉素试剂和参比制剂于192 h内的血药浓度, 并进行了生物等效性研究.     

高效液相色谱-三重四极杆/复合离子阱质谱测定大鼠血浆中11种合成大麻素

建立并验证了一种用于定量检测大鼠血浆中11种合成大麻素(SCs)的高效液相色谱-串联质谱(HPLC-MS/MS)方法。选择Waters UPLC HSS T3(150 mm×2.1 mm,1.8μm)色谱柱,以乙腈为蛋白沉淀剂(血浆∶乙腈=1∶9,V/V),实现了11种目标物质的色谱分离和检测。方法学验证数据表明,本方法在0.05～10 ng/mL范围内具有良好线性(R²>0.991),基质效应为69.5%～119.0%,回收率为43.8%～131.5%,相对标准偏差为4.0%～28.3%,定量限为0.05～1 ng/mL。本方法适用于血浆中SCs的定性定量检测。     

Liquid chromatography/electrospray ionization mass spectrometry method for the quantification of valproic acid in human plasma

A simple, sensitive and rapid liquid chromatography/electrospray ionization mass spectrometry (LC/ESI-MS) method was developed and validated for the quantification of valproic acid, an antiepileptic drug, in human plasma using benzoic acid as internal standard (IS). Following solid-phase extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase C18 column and analyzed by MS in the single ion monitoring mode using the respective [M-H]- ions, m/z 143 for valproic acid and m/z 121 for the IS. The assay exhibited a linear dynamic range of 0.5-60 microg/mL for valproic acid in human plasma. The lower limit of quantification was 500 ng/mL with a relative standard deviation of less than 10%. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The average absolute recoveries of valproic acid and the IS from spiked plasma samples were 96.1+/-4.2 and 95.6+/-2.7%, respectively. A run time of 4.5 min for each sample made it possible to analyze more than 250 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability and bioequivalence studies.     

Selective and sensitive determination of bis(7)-tacrine, a high erythrocyte binding acetylcholinesterase inhibitor, in rat plasma by high-performance liquid chromatography-tandem mass spectrometry

The current study aims to develop a specific and sensitive LC-MS/MS method for determination of bis(7)-tacrine (B7T) in rat plasma. A 100 microL plasma sample was extracted with ethyl acetate. B7T and the internal standard (IS), pimozide, in the samples were then analyzed with LC-MS/MS in positive electrospray ionization condition. Chromatographic separation of B7T and IS was achieved in a C(18) reversed-phase HPLC column (150 x 2.1 mm i.d.) by isocratic elution with a mobile phase consisting of 0.05% formic acid in water and acetonitrile (1:1, v/v) at a flow rate of 0.35 mL/min. Multiple-reaction monitoring (MRM) mode was employed to measure the ion transitions: m/z 247 to 197 for B7T and m/z 462 to m/z 328 for IS, respectively. The method was linear over the studied ranges of 100-5000 and 10-100 ng/mL. The intra-day and inter-day variations of the analysis were less than 6.8% with standard errors less than 9.0%. The detection limit of B7T in rat plasma was 1 ng/mL. The developed method was successfully applied to the pharmacokinetic study of B7T after intravenous administration of 1 mg/kg B7T and further proved to be readily utilized for determination of B7T in rat plasma samples.     

Simultaneous quantification of fexofenadine and pseudoephedrine in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: method development, validation and application to a clinical study

To support the pharmacokinetic and bioavailability study of a once-daily fexofenadine/pseudoephedrine combination, a high-performance liquid chromatography/positive ion electrospray tandem mass spectrometry (HPLC/ESI-MS/MS) method for the simultaneous quantification of fexofenadine and pseudoephedrine was developed and validated with 500 microL human plasma using mosapride as an internal standard (IS). Following solid-phase extraction, the analytes were separated using an isocratic mobile phase on a reversed-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M+H]+ ions, m/z 502/466 for fexofenadine, m/z 166/148 for pseuoephedrine and m/z 422/198 for the IS. The method exhibited linear dynamic ranges of 1-500 ng/mL and 2-1000 ng/mL for fexofenadine and pseudoephedrine, respectively, in human plasma. The lower limits of quantification were 1 and 2 ng/mL with a relative standard deviation of less than 10% for fexofenadine and pseudoephedrine, respectively. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The total chromatographic run time was 2 min and more than 400 human plasma samples could be analyzed in one day by running the system overnight. The method is precise and sensitive enough for its intended purpose.     

High performance liquid chromatographic-mass spectrometric assay for the quantitation of BMS-204352 in dog K(3)EDTA plasma

A high performance liquid chromatographic-mass spectrometric (LC/MS) assay was developed and validated for the determination of BMS-204352 in dog K(3)EDTA plasma. A 0.5 mL aliquot of control plasma was spiked with BMS-204352 and internal standard (IS) and buffered with 1 mL of 5 mM ammonium acetate. The mixture was then extracted with 3 mL of toluene. After separation and evaporation of the organic phase to dryness using nitrogen at 40 degrees C, the residue was reconstituted in the mobile phase and 25 microL of the sample were injected onto a Hypersil C(18) column (2 x 50 mm; 3 microm) at a flow rate of 0.5 mL/min. The mobile phase was consisted of two solvent mixtures (A and B). Solvent A was composed of 5 mM ammonium acetate and 0.1% triethylamine in 75:25 v/v water:methanol, pH adjusted to 5.5 with glacial acetic acid, and solvent B was 5 mM ammonium acetate in methanol. A linear gradient system was used to elute the analytes. The mass spectrometer was programmed to admit the de-protonated molecules at m/z 352.7 (IS) and m/z 357.9 (BMS-204352). Standard curves of BMS-204352 were linear (r(2) > or = 0.998) over the concentration range of 0.5-1000 ng/mL. The mean predicted quality control (QC) concentrations deviated less than 5.1% from the corresponding nominal values (ie 4, 80, 400 and 2000 ng/mL); the within- and between-assay precision of the assay were within 5.5% relative standard deviation. Stability of BMS-204352 was confirmed after at least three freeze/thaw cycles and BMS-204532 was stable in dog plasma when stored frozen at or below -20 degrees C for at least 16 weeks in spiked QC samples and for at least 4 1/2 weeks for in vivo study samples. BMS-204352 and IS were stable in the injection solvent at room temperature for at least 24 h. The assay was applied to delineate the pharmacokinetic disposition of BMS-204352 in dogs following a single intravenous dose administration. In conclusion, the assay is accurate, precise, specific, sensitive and reproducible for the pharmacokinetic analysis of BMS-204532 in dog plasma.     

超高效液相色谱-串联质谱法测定犬血浆中利培酮和帕潘立酮及药代动力学研究

建立了超高效液相色谱-串联质谱法(UPLC-MS/MS)测定犬血浆中利培酮和帕潘立酮的浓度.血浆样品用乙腈沉淀蛋白后,用Zorbax SB-C18柱分离,以乙腈-10 mmol/L乙酸铵溶液(65∶35,V/V)为流动相,在电喷雾离子源正离子模式下以多反应监测(MRM)方式进行检测.利培酮、帕潘立酮分别在0.05～30.0 ng/mL和0.10～30.0 ng/mL范围内线性关系良好(r2＞0.99),定量限分别为0.05 ng/mL和0.10 ng/mL,回收率分别为91.2％～95.1％和93.1％～97.5％.该方法精密、准确、快速,适用于临床血药浓度的监测及利培酮缓释微球药动学的研究.     

液相色谱-串联质谱法同时测定动物血浆中21种霉菌毒素或其代谢物残留

建立了同时检测动物血浆中黄曲霉毒素B1等21种霉菌毒素或其代谢物残留的液相色谱-串联质谱方法.动物血浆样品中加入0.1％甲酸-乙腈溶液、NaCl和无水MgSO4进行萃取,无水MgSO4和C18,PSA,A-AL对提取液进行脱水净化,经浓缩、复溶和离心后,再进行测定.采用反相C18色谱柱分离,以0.1％甲酸-0.5 mmol/L乙酸铵溶液和0.1％甲酸-甲醇溶液作为流动相进行梯度洗脱,采用电喷雾离子源(ESI)多反应监测离子模式(MRM)进行检测,基质标准曲线外标法进行定量分析,线性范围在0.05 ～ 100 ng/mL之间,方法的定量限为0.05 ～0.5 ng/mL.在高、中、低3个添加浓度水平下,21种霉菌毒素的平均回收率为62.0％ ～ 116.4％,相对标准偏差小于19％.     

Simultaneous determination of triptolide, tripdiolide and tripterine in human urine by high-performance liquid chromatography coupled with ion trap atmospheric-pressure chemical ionization mass spectrometry

An accurate and selective method for the simultaneous determination of triptolide, tripdiolide and tripterine in human urine using hydrocortisone as an internal standard (IS) by high-performance liquid chromatography coupled with atmospheric-pressure chemical ionization mass spectrometry in negative ion mode has been developed. After triptolide, tripdiolide and tripterine in human urine were extracted with ethyl acetate and cleaned by solid-phase extraction with C(18) cartridges, a satisfactory separation was achieved on an XDB C(18) short column (30 x 2.1 mm i.d., 3 microm) using the mobile phase of acetic acid-ammonium acetate (5 mmol/L, pH = 4.5)-acetonitrile-methanol in gradient elution. Detection was operated by APCI in selected ion monitoring mode. The target ions m/z 359, m/z 375, m/z 449 and m/z 419 were selected for the quantification of triptolide, tripdiolide, tripterine and IS, respectively. The linear range was 1.0-100.0 ng mL(-1), and the limits of quantification in human urine were found to be 0.1-0.5 ng mL(-1) for the three compounds. The precisions (CV%) and accuracies were 6.6-12.9 and 85.1-97.0%, respectively. The developed method could be applied to the determination of triptolide, tripdiolide and tripterine in human urine for diagnosis of the intoxication and for forensic purposes.     

Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry

A high-performance liquid chromatography/positive ion electrospray tandem mass spectrometry method for the simultaneous quantification of efavirenz, emtricitabine and tenofovir was developed and validated with 100 microL human plasma. Following solid-phase extraction, the analytes were separated using a gradient mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective [M + H]+ ions, m/z 316 to 168 for efavirenz, m/z 248-130 for emtricitabine and m/z 288-176 for tenofovir, m/z 482-258 for rosuvastatin (IS), m/z 260-116 for propranolol (IS). The method exhibited a 100-fold linear dynamic range for all the three analytes in human plasma (20-2000, 2-200 and 20-2000 ng/mL for efavirenz, emtricitabine and tenofovir respectively). The lower limit of quantification was 2 ng/mL for emtricitabine and 20 ng/mL for both efavirenz and tenofovir with a relative standard deviation of less than 11%. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The total chromatographic run time of 4 min for each sample made it possible to analyze more than 250 human plasma samples per day. The method is precise and sensitive enough for its intended purpose. The method is also successfully applied to quantify efavirenz, emtricitabine and tenofovir concentrations in a rodent pharmacokinetic study.     

Simultaneous determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using ultra-performance liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study

A rapid, sensitive, and simple ultra-performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) method for the determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using sildenafil as an internal standard (IS) was developed and validated. Udenafil, DA-8164 and IS from a 100 microL aliquot of biological samples were extracted by protein precipitation using acetonitrile. Chromatographic separation was carried on an Acquity UPLC BEH C(18) column (50 x 2.1 mm, i.d., 1.7 microm) with an isocratic mobile phase consisting of acetonitrile and containing 0.1% formic acid (75:25, v/v) at flow rate of 0.4 mL/min, and total run time was within 1 min. Detection and quantification was performed by the mass spectrometer using multiple reaction-monitoring mode at m/z 517 --> 283 for udenafil, m/z 406 --> 364 for DA-8164 and m/z 475 --> 100 for IS. The assay was linear over a concentration range of 1-600 ng/mL with a lower limit of quantification of 1 ng/mL in both human plasma and urine. The coefficient of variation of this assay precision was less than 13.7%, and the accuracy exceeded 92.0%. This method was successfully applied for pharmacokinetic study after oral administration of udenafil 100 mg to healthy Korean male volunteers.     

A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study

A rapid and high sensitive liquid chromatography-tandem mass spectrometry (LC-MS-MS) method was developed and validated for the quantification of zolpidem in human EDTA plasma using ondansetron (IS) as an internal standard. The analyte and IS were extracted from human plasma using ethyl acetate and separated on a C18 column (Inertsil-ODS, 5 μm, 4.6 × 50 mm) interfaced with a triple quadrupole tandem mass spectrometer. The mobile phase, which consisted of a mixture of methanol and 20 mM ammonium formate (pH 5.00 ± 0.05; 75:25 v/v), was injected at a flow rate of 0.40 mL/min. The retention times of zolpidem and IS were approximately 1.76 and 1.22. The LC run time was 3 min. The electrospray ionization source was operated in positive ion mode. Multiple reaction monitoring used the [M + H](+) ions m/z 308.13 → 235.21 for zolpidem and m/z 294.02 → 170.09 for the ondansetron, respectively. Five freeze-thaw cycles was established at -20 and -70°C.The linearity of the response/concentration curve was established in human EDTA plasma over the concentration range 0.10-149.83 ng/mL. The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL. This LC-MS-MS method was validated with intra-batch and inter-batch precision of 0.52-8.66.The intra-batch and inter-batch accuracy was 96.66-106.11. Recovery of zolpidem in human plasma was 87.00% and IS recovery was 81.60%. The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.